Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAAShell Companies
+$0.00 today
- Market cap
- $264.62M
- Beta
- 0.00
- P/E (TTM)
- 36.7
- EPS (TTM)
- $0.29
Volume 0.00M
Average 0.11M
DMAA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $143.3K fell 56.7% year over year, behind the +96.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 63.8% from the prior quarter.
What to watch
Whether quarterly growth recovers from -56.7% toward the trailing-twelve-month pace of +96.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 2.82M USD
- Year-over-year change
- +586894.7%
- 1-year CAGR
- +586894.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.82M | +586894.7% |
| FY2024 | 2024-12-31 | 480 | — |
Selling, General & Admin vs competitors
How DMAA compares with its peers on the latest reported figures
- DMAA's LTM Mar 2026 selling, general & admin of $934.55K is the 6th highest of the 10 companies compared; the peer median is $1.11M.
- Its year-over-year change of +96.3% is the 3rd highest of 5, against a peer median of +801.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.06M | — | — | — | |
TACHTitan Acquisition Corp. | LTM Mar 2026 | $1.69M | +667097.0% | — | — |
| LTM Mar 2026 | $1.18M | +1590.4% | — | — | |
TACOUBerto Acquisition Corp. Unit | LTM Mar 2026 | $1.11M | — | — | — |
| LTM Mar 2026 | $1.11M | — | — | — | |
| LTM Mar 2026 | $934.55K | +96.3% | — | — | |
| LTM Mar 2026 | $891.28K | +13.0% | — | — | |
OYSEOyster Enterprises II Acquisition Corp | LTM Mar 2026 | $599.68K | — | — | — |
| LTM Mar 2026 | $465.41K | — | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding DMAA) | $1.11M | +801.7% | — | — | |
Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Gross Margin | — | — |
| Research & Development | 0 | 0 |
| Selling, General & Admin | 480 | 2.82M |
| Operating Expenses | 480 | 2.82M |
| Depreciation & Amortization | 480 | 0 |
| EBITDA | (279.85K) | (2.82M) |
| EBITDA Margin | — | — |
| Operating Income | (479) | (2.82M) |
| Operating Margin | — | — |
| Interest Income | 0 | 8.76M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 0 | 8.76M |
| Income Before Tax | (479) | 5.94M |
| Pre-Tax Margin | — | — |
| Income Tax Expense | 0 | 0 |
| Net Income | (479) | 5.94M |
| Net Margin | — | — |
| EPS (Basic) | (0.06) | 0.19 |
| EPS (Diluted) | (0.06) | 0.19 |
| Weighted Avg Shares | 8.57M | 21.01M |
| Weighted Avg Shares (Diluted) | 8.57M | 21.01M |
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.